including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can continue to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new radionuclide generators, which can effectively alleviate the shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can continue to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new radionuclide generators, which can effectively alleviate the shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, and innovations in products and technologies will redefine the next generation of radiopharmaceuticals
View more
South African skin cancer patients undergo first treatments with OncoBeta's Rhenium-SCT as part of the EPIC-Skin study
POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
Trends in the number of radiology studies and a decline in radiation dose
Trial of PSMA-PET imaging agent 64Cu-SAR-bisPSMA meets primary end points
Novartis Pluvicto shows survival benefit in prostate cancer patients in phase 3 trial
3D printing can help produce valuable radiopharmaceuticals
